SCHEMBL3226522

SCHEMBL3226522

Cc1ccc(C(=O)N2CCOCC2)cc1C(N)=O

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.68
GAA P10253 2/20 0.60
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
PKM P14618 1/20 0.55
MYC P01106 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
MAPT P10636 1/20 0.52
HTT P42858 1/20 0.52
HSP90AA1 P07900 2/20 0.52
HSP90AB1 P08238 2/20 0.52
KMT2A Q03164 2/20 0.52
PHGDH O43175 1/20 0.51
GLA P06280 1/20 0.51
RAB9A P51151 2/20 0.51
NPC1 O15118 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233250 0.90 HPGD (0.65) HPGDGAAALDH1A1KDM4EPKM
SCHEMBL3231384 0.84 KMT2A (0.56) HPGDALDH1A1KMT2A
SCHEMBL12311738 0.83 HPGD (0.77) HPGDGAAALDH1A1KDM4EPKM
SCHEMBL3226524 0.82 HPGD (0.71) HPGDGAAALDH1A1KDM4EPKM
SCHEMBL13161947 0.81 HPGD (1.00) HPGDGAAALDH1A1KDM4EPKM
SCHEMBL3226312 0.81 ALDH1A1 (0.48) HPGDALDH1A1KDM4ESMN1; SMN2KMT2A
SCHEMBL2376730 0.79 HPGD (0.67) HPGDGAAALDH1A1KDM4EPKM
SCHEMBL12547416 0.79 HPGD (0.71) HPGDGAAALDH1A1KDM4EPKM
SCHEMBL10194842 0.79 HPGD (0.71) HPGDGAAALDH1A1KDM4EPKM
SCHEMBL2376032 0.79 HPGD (0.75) HPGDGAAALDH1A1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP claimed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US claimed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP claimed
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 HPGD 1383/4885GAA 2827/4885ALDH1A1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.